Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Feb 14, 2005; 11(6): 785-790
Published online Feb 14, 2005. doi: 10.3748/wjg.v11.i6.785
Published online Feb 14, 2005. doi: 10.3748/wjg.v11.i6.785
Table 1 Cell cycle distribution of SW480 cells transfected with telomerase ASODNs, SODNs and OligofectamineTM (mean±SD, n = 3).
| Cell cycle distribution (%) | |||
| G0/G1 | S | G2/M | |
| Control | 50.7±2.3 | 36.6±1.8 | 15.5±2.2 |
| OligofectamineTM | 53.8±2.7 | 34.1±3.6 | 12.3±2.6 |
| S-hTR | 53.1±2.8 | 34.4±13.2 | 12.5±1.3 |
| S-hTERT | 50.7±3.5 | 30.1±2.8 | 19.2±2.6 |
| Anti-hTR | 55.0±2.3 | 30.1±2.5 | 14.9±1.9 |
| Anti-hTERT | 49.2±3.4 | 28.8±3.1 | 21.9±2.8b |
| Anti- hTR+anti-hTERT | 63.8±2.3b | 24.9±1.6 | 12.3±2.9 |
- Citation: Fu XH, Zhang JS, Zhang N, Zhang YD. Combination of telomerase antisense oligonucleotides simultaneously targeting hTR and hTERT produces synergism of inhibition of telomerase activity and growth in human colon cancer cell line. World J Gastroenterol 2005; 11(6): 785-790
- URL: https://www.wjgnet.com/1007-9327/full/v11/i6/785.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i6.785